Option chain shows key data for Synlogic's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Synlogic.

Synlogic (NASDAQ:SYBX) Stock, Option Chain

Synlogic

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Biotech

Penny Stocks

Markets

Trading Ideas

General

BRNS

SYBX

Synlogic, Inc. (NASDAQ: SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

vaccine-4892048

News

Synlogic shares are trading lower by 48.4% to $1.78 Friday afternoon. The company announced it will discontinue Synpheny-3, cease operations and reduce its workforce by more than 90%.

Why Synlogic (SYBX) Stock Is Down Nearly 50% Today

Earnings

Eurozone

Commodities

Global

Intraday Update

DOOR

EMKR

Intelligent Bio Solutions Inc. - Common Stock

INBS

PLCE

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Friday.

The Dow traded down 0.09% to 38,691.21 while the NASDAQ rose 1.26% to 15,992.17. The S&amp;P 500 also rose, gaining, 0.55% to 5,025.21.

Crude Oil Moves Higher; Newell Brands Issues Weak Outlook

Synlogic Inc

Press Releases

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Synlogic Reports First Quarter 2024 Financial Results

Synlogic Reports Second Quarter 2024 Financial Results

Synlogic Reports Third Quarter 2024 Financial Results

LCTX

ABVC BioPharma

Aprea Therapeutics

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Eterna Therapeutics

GlycoMimetics

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Imunon

IN8bio

Kairos Pharma

Leap Therapeutics

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

MetaVia

NextCure

BiomX

SAB Biotherapeutics

Senti Biosciences

Spruce Biosciences

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Leerink Partners

Alliance Global Partners

Oppenheimer

Comments

Synlogic

Synlogic (SYBX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga